UBS Raises Price Target for Pfizer

UBS analysts have updated their assessment of the pharmaceutical sector and increased the price target for Pfizer. The analysis reviewed the company's specific product portfolio and future period expectations. The bank revised its optimistic view regarding the company's performance potential in certain areas. This update resulted in a price target exceeding the previously set level. The financial institution's report was prepared as part of a broader sector outlook. Investors continue to closely monitor market conditions and company performance. Not an investment recommendation.

📊 PFE — Piyasa Yorumu

▲ up · 65%

The headline indicates a generally positive development, such as an investment bank raising its price target. Technical indicators also support a slight upward trend in the short term: the stock's last closing is above the 20- and 50-day moving averages, the RSI at 61 is in neutral territory but leaves room for an increase, and the MACD is in positive territory above the signal line. However, the fact that the RSI has not yet entered overbought territory and the position above the moving averages create a positive bias, albeit with limited confidence. A limited rise can be expected in the short term.

RSI 14

61.4

MACD

0.09

24h Δ

1.21%

Canlı Grafikler